A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer

Prior treatment

• Having received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used for the treatment of thrombocytopenia) within 2 weeks before the first dose;
• Having received Chinese herbal medicines or proprietary Chinese medicines with anti-tumor indications within 1 week before the first dose;
• Having a history of immunodeficiency; positive HIV antibody test; currently receiving long-term systemic corticosteroids or other immunosuppressants;
• Subjects with evidence or history of thrombosis or obvious bleeding tendency within 2 months before the first administration of the study drug (bleeding \> 30 mL within 2 months, with hematemesis, melena, hematochezia), hemoptysis (\> 5 mL of fresh blood within 4 weeks);

Other illness

• Subjects with rare histopathological types of cervical cancer, such as neuroendocrine carcinoma, sarcoma, etc.;
• Subjects who have had other malignant tumors within 3 years before enrollment, except for cervical cancer. Subjects with other malignant tumors that have been cured by local treatment are not excluded, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, breast carcinoma in situ, etc.;
• A history of allergic reactions, hypersensitivity reactions, or intolerance to antibody-based drugs; a history of significant allergies to drugs, food, or other substances;
• Having active autoimmune diseases requiring systemic treatment within the past two years;
• Having a history of non-infectious pneumonia requiring systemic glucocorticoid treatment, a history of pneumonia, or a current history of interstitial lung disease;
• A known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;
• Having uncontrolled comorbidities, including but not limited to: active HBV or HCV infection; known HIV infection or AIDS history; active syphilis; active tuberculosis; active infection; uncontrolled hypertension, symptomatic cardiac insufficiency; active bleeding;
• Active or uncontrolled severe infections (≥ CTCAE5.0 grade 2 infections), including but not limited to hospitalization due to infectious complications, bacteremia or severe pneumonia, and unexplained fever \> 38.5℃ before the first dose;
• A clear history of mental disorders (including epilepsy or dementia); or other conditions that the investigator deems inappropriate for participation in the study;

Other

• Patients participating in other clinical trials at the same time, unless they are in an observational, non-interventional clinical study or the follow-up period of an interventional study;
• Those with no measurable lesions or unevaluable lesions;
• Pregnant or lactating women;
• Patients who the investigator judges are unlikely to comply with the study procedures, restrictions, and requirements must not participate in this study.

• Age: 18-75 years old, female;
• No prior systemic anti-tumor treatment (including chemotherapy, radiotherapy, or other investigational treatments);
• PD-L1 test result: CPS ≥ 1;
• Presence of measurable lesions at baseline according to RECIST 1.1 criteria;
• Pathological types: squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma;
• FIGO 2018 stage: IA, IB1-2, IIA1, IB3, IIA2;
• ECOG PS: 0-1;
• Expected survival period \> 3 months;
• Good function of major organs, meeting the following criteria:
  • Blood routine examination (without blood transfusion or use of hematopoietic stimulating factors to correct the condition within 14 days): hemoglobin (Hb) ≥ 90g/L; absolute neutrophil count (ANC) ≥ 1.5×10⁹/L; platelets (PLT) ≥ 90×10⁹/L;
  • Biochemical examination: alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5×ULN (for patients with liver metastases, ≤ 5×ULN); serum total bilirubin (TBIL) ≤ 1.5×ULN (for subjects with Gilbert syndrome, ≤ 3×ULN); serum creatinine (Cr) ≤ 1.5×ULN, or creatinine clearance ≥ 60mL/min;
  • Coagulation function: activated partial thromboplastin time (APTT), international normalized ratio (INR), prothrombin time (PT) ≤ 1.5×ULN;
  • Urinalysis shows urine protein \< 2+; if urine protein ≥ 2+, 24-hour urine protein quantification should be \< 1g;
  • Doppler ultrasound assessment: left ventricular ejection fraction (LVEF) ≥ 50%.
• Women of childbearing age must agree to use contraceptive measures (such as intrauterine devices, contraceptives, or condoms) during the study and within 6 months after the end of the study; serum or urine pregnancy test within 7 days before enrollment must be negative, and they must be non-lactating patients; male patients must agree to use contraceptive measures during the study and within 6 months after the end of the study;
• Subjects voluntarily participate in this study, sign the informed consent form, have good compliance, and cooperate with follow-up.